Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MADIT-II: substudies and their implications.

Arthur J Moss1,

  • 1University of Rochester Medical Center, Rochester, New York, USA. heartajm@heart.rochester.edu

Cardiac Electrophysiology Review
|April 9, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low magnetic fields stimulate cardiac mitochondrial bioenergetics with a bell-shaped response: Possibly via a radical pair mechanism.

Computational and structural biotechnology journal·2025
Same author

Heritability in genetic heart disease: the role of genetic background.

Open heart·2019
Same author

Long-term outcomes of cardiac resynchronization therapy by left ventricular ejection fraction.

European journal of heart failure·2018
Same author

Left Ventricular Lead Location and Long-Term Outcomes in Cardiac Resynchronization Therapy Patients.

JACC. Clinical electrophysiology·2018
Same author

Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial.

Journal of the American College of Cardiology·2018
Same author

Risk Stratification of Type 2 Long-QT Syndrome Mutation Carriers With Normal QTc Interval: The Value of Sex, T-Wave Morphology, and Mutation Type.

Circulation. Arrhythmia and electrophysiology·2018
Same journal

Cost-effectiveness of the implantable cardioverter defibrillator.

Cardiac electrophysiology review·2004
Same journal

Clinical significance of device-related complications in clinical trials and implications for future trials: insights from the Antiarrhytmics Versus Implantable Defibrillators (AVID) trial.

Cardiac electrophysiology review·2004
Same journal

The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial: rationale, design, results, clinical implications and lessons for future trials.

Cardiac electrophysiology review·2004
Same journal

Clinical trials of prophylactic implantable defibrillator therapy in patients with nonischemic cardiomyopathy: what have we learned and what can we expect from future trials?

Cardiac electrophysiology review·2004
Same journal

DEFibrillators In Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE).

Cardiac electrophysiology review·2004
Same journal

Amiodarone versus Implantable Defibrillator (AMIOVIRT): background, rationale, design, methods, results and implications.

Cardiac electrophysiology review·2004
See all related articles

Prophylactic implantable cardioverter-defibrillator (ICD) therapy significantly improves survival in patients with prior myocardial infarction and low ejection fraction. ICDs provide life-saving therapy for ventricular arrhythmias in over a third of patients within four years.

Area of Science:

  • Cardiology
  • Medical Devices
  • Clinical Trials

Background:

  • The MADIT-II trial investigated the efficacy of prophylactic implantable cardioverter-defibrillators (ICDs) in patients with prior myocardial infarction and reduced ejection fraction.
  • Previous studies suggested benefits of ICDs in specific patient populations, necessitating further evaluation in broader groups.

Purpose of the Study:

  • To assess the effectiveness of prophylactic ICD therapy in improving survival rates for patients with prior myocardial infarction and ejection fraction less than or equal to 0.30.
  • To determine if traditional risk factors could identify subgroups benefiting more from ICD therapy.

Main Methods:

  • Analysis of data from the MADIT-II clinical trial.
  • Inclusion of patients with prior myocardial infarction and ejection fraction <= 0.30.

Related Experiment Videos

  • Prespecified secondary analyses to evaluate subgroup efficacy.

    • Main Results:

    • Prophylactic ICD therapy demonstrated a significant survival benefit in the studied patient cohort.
    • The life-saving effect of ICD therapy was consistent across all examined subgroups.
    • No traditional risk factors were identified to reliably select patients for superior ICD benefit.
    • Appropriate ICD therapy for life-threatening ventricular arrhythmias occurred in over one-third of patients within four years.
    • Nine patients required ICD treatment over four years to save one life (Number Needed to Treat).

    Conclusions:

    • Prophylactic ICD therapy is effective in improving survival for patients with prior myocardial infarction and low ejection fraction.
    • The benefits of ICDs are broadly applicable across subgroups, without clear selection by traditional risk factors.
    • The findings have significant implications for patient selection, physician decision-making, and healthcare resource allocation regarding ICD implantation.